A New Treatment for Knee Osteoarthritis Pain on the Horizon
There should soon be a new kid on the block for knee osteoarthritis pain management.
Centrexion, a company focused on developing non-opioid, non-steroidal therapeutics for treating pain, announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to CNTX-4975 for the treatment of knee osteoarthritis pain. CNTX-4975 is a synthetic, ultra-pure injection of trans-capsaicin (derived from the chili plant) designed to be administered directly into the knee joint to provide rapid and long-lasting pain relief.
“This is an important milestone for both Centrexion and the millions of people suffering from pain associated with knee osteoarthritis. With the Fast Track approval, we look forward to additional interactions with the FDA to optimize the development of this novel, non-opioid, non-addictive pain treatment,” said Randall Stevens, M.D., Chief Medical Officer for Centrexion. He goes on to say “Osteoarthritis is a rapidly escalating public health issue projected to affect nearly 67 million Americans by 2030 – it is absolutely critical that we continue to advance new pain treatments like CNTX-4975 that have the potential to relieve pain and improve stiffness and function, while avoiding the significant challenges and side effects of currently available therapies. We look forward to building on the momentum of our CNTX-4975 program with the initiation of our Phase 3 program in patients with moderate to severe knee osteoarthritis in the first quarter of 2018.”
CNTX-4975 works by targeting the capsaicin receptor to selectively and rapidly inactivate the local pain fibers which transmit pain signals to the brain. With a short half-life, CNTX-4975 is cleared from the body within 24 hours. This approach is designed to provide pain relief that can last for months until the ends of the local pain fibers regenerate, while maintaining normal sensations like touch, pressure and position, without the risks that plague current NSAID, injected corticosteroid and opioid treatments.
For more information about Centrexion, visit their website: http://www.centrexion.com.